Dublin, April 24, 2026 (GLOBE NEWSWIRE) — The “Omics-Based Clinical Trials Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The omics-based clinical trials market is on a robust growth trajectory, anticipating an increase from $31.71 billion in 2025 to $34.49 billion by 2026, with a CAGR of 8.8%. This expansion is propelled by the complexity of clinical trial designs, advancements in genomic and proteomic research, demand for personalized therapies, enhanced research infrastructure, and collaborations between pharmaceutical companies and academic institutions.
Looking ahead, the market is projected to surge to $47.78 billion by 2030, maintaining a CAGR of 8.5%. Drivers include the adoption of precision medicine, increased investment in data-driven trials, AI-enhanced patient recruitment, regulatory acceptance of omics endpoints, and the demand for efficient outcomes. Key trends include biomarker-driven designs, multi-omics patient stratification, real-world evidence integration, and precision oncology expansion.
The surge in personalized medicine demand significantly contributes to the omics-based clinical trials market’s growth. This approach leverages advances in genomic technologies to offer tailored disease treatments. With FDA approving 16 new personalized treatments in 2023, including oncology therapies, the momentum continues strong. Personalized medicine’s increasing relevance underscores the necessity for clinical trials tailored to genetic, proteomic, and metabolic profiles, enhancing patient-specific strategies.
Innovation remains central, with companies focusing on technologies like HiFi sequencing to enhance multi-omics data analysis. Notably, Pacific Biosciences of California Inc. partnered with A*STAR and Macrogen Inc. to launch a Singapore-based lab championing high-precision genomics studies. This facility bolsters personalized medicine, rare disease diagnostics, and precision oncology while facilitating regional scientific collaborations and training in next-generation sequencing.
In strategic movements, Bruker Corporation acquired Biocrates Life Sciences AG in June 2025 to enrich its multiomics solutions through metabolomics technology integration. Biocrates specializes in omics-based trial solutions, advancing standardized, reproducible workflows for life and clinical sciences research.
Leading industry players include Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc., and Eli Lilly and Company, among others. North America leads the market, yet Asia-Pacific is poised for rapid expansion. Global regions encompassed in market analysis include Asia-Pacific, Western and Eastern Europe, North America, South America, the Middle East, and Africa, covering countries like the USA, China, and Germany among others.
Tariffs present challenges, hiking costs for imported sequencing tools and extending study budgets, especially affecting North America and Europe’s pharmaceutical sectors. This dynamic promotes local services and regional collaborations, encouraging domestic development in analytics and clinical research.
The comprehensive omics-based clinical trials market report includes industry statistics, trends, and opportunities for growth. Covering genomics, proteomics, transcriptomics, and metabolomics, these trials are essential across therapeutic areas like oncology and neurology. The market is characterized by revenues from services such as genomics analysis, platform sales, and bioinformatics tools.
Values are delineated as ‘factory gate’ values, encompassing the revenues from direct sales as well as associated services. Revenues reflect consumption values generated in specified geographies, excluding downstream supply chain resales.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $34.49 Billion |
| Forecasted Market Value (USD) by 2030 | $47.78 Billion |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
Key Technologies & Future Trends
- Biotechnology, Genomics & Precision Medicine
- Artificial Intelligence & Autonomous Intelligence
- Digitalization, Cloud, Big Data & Cybersecurity
- Industry 4.0 & Intelligent Manufacturing
- Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
- Increasing Adoption of Biomarker-Driven Trial Designs
- Rising Use of Multi-Omics Patient Stratification
- Growing Integration of Real-World Evidence Analytics
- Expansion of Precision Oncology Clinical Trials
- Enhanced Focus on Data-Centric Trial Optimization
Companies Featured
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- GlaxoSmithKline Plc
- Eli Lilly and Company
- Novo Nordisk A/S
- BioNTech SE
- IQVIA Inc.
- Laboratory Corporation of America Holdings
- ICON Public Limited Company
- SGS Societe Generale de Surveillance SA
- Eurofins Scientific SE
- Syneos Health Inc.
- Illumina Inc.
- Charles River Laboratories International Inc.
- Parexel International Corporation
- Bruker Corporation
- Fulgent Genetics Inc.
- Signios Biosciences
- BioAro Inc.
For more information about this report visit https://www.researchandmarkets.com/r/n9oaqg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Omics-Based Clinical Trials Market
